June 16, 2026 03:05 PM EDTUpdated 03:22 PM
R&DCell/Gene Tx
B cell therapy maker Be Bio stops hemophilia trial
Lei Lei Wu
News Reporter
B cell therapy maker Be Bio stops hemophilia trial
Be Biopharma disclosed in a federal clinical trials listing that it has terminated its study of a hemophilia B therapy made by editing a patient’s own cells. It was one of just a few trials examining a B cell therapy.
TL;DRAI
Be Bio halted its hemophilia B cell therapy trial. This signals execution risk in gene/cell tx—late-stage failures compress commercialization timelines and impact biotech investment allocation.
135 words~1 min read
